Jennifer Pohlmann-Patterson, MD
Internal Medicine · Richardson, TXNPI 1942221510
Payments from drug & device makers
Across 416 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$845
- GSK$431
- Lilly USA, LLC$403
- Pfizer$393
- Otsuka America Pharmaceutical, Inc.$364
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,099100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 100 | $1,298 |
| AbbVie(2 entities) | 55 | $845 |
| GSK | 31 | $431 |
| Lilly USA, LLC | 31 | $403 |
| Pfizer | 22 | $393 |
| Otsuka America Pharmaceutical, Inc. | 21 | $364 |
| AstraZeneca | 12 | $239 |
| Amarin Pharma, Inc. | 14 | $226 |
| Boehringer Ingelheim | 16 | $226 |
| Amgen | 13 | $208 |
| Radius Health, Inc. | 11 | $196 |
| Merck | 17 | $192 |
| Sanofi-aventis U.S. LLC | 11 | $152 |
| Amneal Pharmaceuticals LLC | 7 | $102 |
| Johnson & Johnson | 7 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $83 |
| Endo Pharmaceuticals Inc. | 5 | $82 |
| Eisai Inc. | 5 | $72 |
| Dexcom, Inc. | 4 | $69 |
| Astellas Pharma US Inc | 4 | $66 |
| Exact Sciences | 4 | $64 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Genentech USA, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Abbott | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$6,118 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $137,907 |
| JardianceEmpagliflozin | 109 | $109,039 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $26,979 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $25,861 |
| RybelsusSemaglutide | 22 | $20,348 |
| XareltoRivaroxaban | 23 | $19,934 |
| FarxigaDapagliflozin Propanediol | 14 | $19,604 |
| VascepaIcosapent Ethyl | 27 | $19,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $18,973 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $9,798 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,785 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $6,459 |
| InvokanaCanagliflozin | 11 | $6,326 |
| PremarinEstrogens, Conjugated | 15 | $5,719 |
| Novolog Mix 70-30Insulin Aspart Prot/Insuln Asp | 12 | $4,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $1,298 | $163,223157 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $226 | $141,358150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $431 | $26,75832 claims |
| Johnson & JohnsonXarelto, Invokana | $86 | $26,26134 claims |
| AstraZenecaFarxiga | $239 | $19,60414 claims |
| Esperion Therapeutics, Inc.Nexlizet | $17 | $9,79819 claims |
| PfizerPremarin | $393 | $5,71915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $102 | $4,212343 claims |
| AbbVieSynthroid | $845 | $4,11663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Richardson
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.